ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:EMBO Mol Med
Hoofdauteurs: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BlackWell Publishing Ltd 2015
Onderwerpen:
Research Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://ncbi.nlm.nih.gov/pubmed/25872941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201404396
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items